6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
about
Major clinical research advances in gynecologic cancer in 2013Progress in adjuvant chemotherapy for breast cancer: an overviewHow Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerBreast cancer in 2013: Genomics, drug approval, and optimal treatment durationUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesTreatment of early-stage HER2+ breast cancer-an evolving fieldSystemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineLong-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsConstitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohortEfficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancerTherapeutic options for HER-2 positive breast cancer: Perspectives and future directionsDose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialTrastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.Optimal systemic therapy for early breast cancer in women: a clinical practice guidelineHER2-directed therapy: current treatment options for HER2-positive breast cancer.Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancerSystematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group.Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patientsMulti-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast CancerPilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)Isolated locoregional recurrence patterns of breast cancer after mastectomy and adjuvant systemic therapies in the contemporary era.Human Epidermal Growth Factor Receptor Expression in Colorectal Cancer and Its Relationship with Clinicopathological Characteristics.Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People's Republic of China.True Local Recurrences after Breast Conserving Surgery have Poor Prognosis in Patients with Early Breast Cancer.A whole-genome sequence and transcriptome perspective on HER2-positive breast cancersTrastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancerTargeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older PatientsCritical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Potential of antibody-drug conjugates and novel therapeutics in breast cancer management.Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab.Clinical practice-changing trials: the HERA study paradigm.Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.
P2860
Q24562146-BE7103AC-C28A-4436-9204-E6B12EC98E59Q26798078-6FDCBDE7-2EE7-4922-BED0-FE805F175D11Q26824542-48225702-1498-443F-A13B-B7B93895343AQ27021514-62F52A08-F821-4782-9683-C521FFC88A48Q27027354-2A6A47F0-71B4-4EBA-9A23-408D69A53D1AQ28072897-388454AB-67F1-4672-987B-B3F30B5CED7FQ28081124-E6DCDF76-8C0D-48A1-8CE6-097768EC8197Q28260063-0B4E3305-2C70-46F4-8BD2-AA1725BFBBBEQ30371966-C4EE8FF9-2AC8-4E16-BA00-F9C9AAD5254AQ30543788-E61955CB-110D-4AD1-AE56-838E1ADF8141Q33644305-571A04C3-CB4C-4DD5-828B-ADDE6DFCE00EQ33731346-15AB7661-8DEC-42A0-85A6-98B6BE545545Q33896941-E73F5EB6-59A0-4A0D-8E45-40BAC9C50860Q34023704-CDB338DF-58A9-401E-B964-66A8F2961328Q34468964-D672DE04-E199-4412-87F4-79A4C25AE0E7Q34484185-F3B02F16-3939-46F3-A2F9-80DD6CC9626FQ34655579-2F7345DA-71EB-4AEB-9D36-C1BB941C434EQ35098320-C4A150BB-3E1B-4BA0-9338-24C9E2BF72E7Q35239634-691744E5-F5D8-4C1B-8F68-BC67D91DE2A1Q35551522-D4207612-EC5C-4AAB-A2D0-F0D276DFB8D8Q35653510-2AF6E654-C5C7-4BF5-A05F-EF033F299871Q35871467-D47CE4D0-966A-4AFA-8E30-EA70DEA15B12Q35880224-899D4EF2-AB57-453B-A239-A84BE4DA5984Q36098713-FD309E00-00CC-464B-8F10-9E5648ECF603Q36169701-67F34063-A5D3-4E8F-AC2B-D753D09F8DA8Q36293907-D1BA3444-A856-4725-9FF4-7329EF823D96Q36382783-2F3EB8B2-3CEA-4798-BE57-F5E0E5E02F25Q36432099-2007E72E-BDBF-4526-AF15-C3687FE609ABQ36546808-7F685B8A-9230-4E0A-9472-2249D0CC7C5BQ36636356-62DECBAD-F2D3-4BD9-9153-3F025C8315E6Q36838741-9DC99329-A3FD-4F99-B159-E90352D246F7Q36839673-4B121B79-2BA5-42D2-9DDE-0D455D11D525Q37099507-399F1E6D-8AC0-4534-BAC8-E906773E405FQ37145885-A6BFEF2F-AC97-4264-83D7-68D431124511Q37191051-28519205-C243-4F60-89F0-D5D6F9A47EF5Q37533025-2F86F7CE-BC42-4ECC-82AF-F647B41355C7Q37671599-A37FB5E8-C455-4D08-B58E-4818B987E2CDQ37735969-BF2F2308-28FC-4FCE-8193-A0CF6580C32DQ38153774-872E9CA9-5CEF-480C-A501-E518919A324CQ38209464-804B494E-B69F-41A2-953E-6C2A557E6CFF
P2860
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
6 months versus 12 months of a ...... ): a randomised phase 3 trial.
@en
6 months versus 12 months of a ...... 2-positive early breast cancer
@nl
type
label
6 months versus 12 months of a ...... ): a randomised phase 3 trial.
@en
6 months versus 12 months of a ...... 2-positive early breast cancer
@nl
prefLabel
6 months versus 12 months of a ...... ): a randomised phase 3 trial.
@en
6 months versus 12 months of a ...... 2-positive early breast cancer
@nl
P2093
P1433
P1476
6 months versus 12 months of a ...... E): a randomised phase 3 trial
@en
P2093
Alain Lortholary
Andrew Kramar
Christelle Jouannaud
Daniel Serin
David Khayat
Gilles Romieu
Iris Pauporté
Jean-Philippe Jacquin
Jean-Yves Pierga
Laurent Cany
P304
P356
10.1016/S1470-2045(13)70225-0
P577
2013-06-11T00:00:00Z